Generic Name and Formulations:
Parathyroid hormone (recombinant) 25mcg, 50mcg, 75mcg, 100mcg; lyophilized pwd for SC inj after reconstitution.
Shire US, Inc.
Indications for NATPARA:
Adjunct to calcium and vitamin D to control hypocalcemia in hypoparathyroidism.
Limitations Of use:
Use only for patients uncontrolled on calcium supplements and active vitamin D alone. Not studied in hypoparathyroidism caused by calcium-sensing receptor mutations or in acute post-surgical hypoparathyroidism.
Individualize based on total serum calcium (albumin-corrected) and 24hr urinary calcium excretion. Give as SC inj in the thigh (alternate thigh daily). Initially 50mcg once daily; may increase in increments of 25mcg every 4 weeks up to max 100mcg daily, if serum calcium is not maintained >8mg/dL. May decrease to 25mcg daily if serum calcium repeatedly >9mg/dL. If currently receiving active vitamin D: decrease vitamin D dose by 50% if serum calcium >7.5mg/dL. Maintenance: use lowest dose to achieve total serum calcium within the lower half of the normal range (approx. 8–9mg/dL). See full labeling.
<18yrs: not established.
Potential risk of osteosarcoma.
Confirm sufficient 25-hydroxyvitamin D stores and serum calcium >7.5mg/dL prior to initiation. Avoid in those with increased baseline risk of osteosarcoma (eg, Paget's disease of bone, unexplained elevations of alkaline phosphatase, pediatric and young adults with open epiphyses, hereditary disorders predisposing to osteosarcoma, history of external beam or implant radiation therapy involving the skeleton). Measure calcium concentration every 3–7 days after starting therapy and when adjusting Natpara, active vitamin D, or calcium supplement doses; consider holding and/or reducing dose if severe hypercalcemia occurs. Renal impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant alendronate: not recommended. Concomitant digoxin: monitor serum calcium and digoxin levels and for digitalis toxicity; adjustments may be needed for both drugs.
Paresthesia, hypocalcemia, headache, hypercalcemia, nausea, hypoaesthesia, diarrhea, vomiting, arthralgia, hypercalciuria, pain in extremity; possibly osteosarcoma.
Multi-dose cartridges (dual-chamber)—2
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness